ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

Junjian Wang, June X. Zou, Xiaoqian Xue, Demin Cai, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C. Yang, Maggie C. Louie, Alexander D. Borowsky, Allen C. Gao, Christopher P. Evans, Kit S. Lam, Jianzhen Xu, Hsing Jien Kung, Ronald M. Evans, Yong Xu, Hong Wu Chen

研究成果: 雜誌貢獻文章

55 引文 (Scopus)

摘要

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.
原文英語
頁(從 - 到)488-496
頁數9
期刊Nature Medicine
22
發行號5
DOIs
出版狀態已發佈 - 五月 1 2016
對外發佈Yes

指紋

Castration
Androgen Receptors
Prostatic Neoplasms
Tumors
Therapeutics
Genes
Nuclear Receptor Coactivator 3
Neoplasms
Nuclear Receptor Coactivator 1
Retinoic Acid Receptors
Gene Regulatory Networks
Response Elements
Transcription
Tumor Cell Line
Heterografts
Toxicity
Cells
Genome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

引用此文

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. / Wang, Junjian; Zou, June X.; Xue, Xiaoqian; Cai, Demin; Zhang, Yan; Duan, Zhijian; Xiang, Qiuping; Yang, Joy C.; Louie, Maggie C.; Borowsky, Alexander D.; Gao, Allen C.; Evans, Christopher P.; Lam, Kit S.; Xu, Jianzhen; Kung, Hsing Jien; Evans, Ronald M.; Xu, Yong; Chen, Hong Wu.

於: Nature Medicine, 卷 22, 編號 5, 01.05.2016, p. 488-496.

研究成果: 雜誌貢獻文章

Wang, J, Zou, JX, Xue, X, Cai, D, Zhang, Y, Duan, Z, Xiang, Q, Yang, JC, Louie, MC, Borowsky, AD, Gao, AC, Evans, CP, Lam, KS, Xu, J, Kung, HJ, Evans, RM, Xu, Y & Chen, HW 2016, 'ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer', Nature Medicine, 卷 22, 編號 5, 頁 488-496. https://doi.org/10.1038/nm.4070
Wang, Junjian ; Zou, June X. ; Xue, Xiaoqian ; Cai, Demin ; Zhang, Yan ; Duan, Zhijian ; Xiang, Qiuping ; Yang, Joy C. ; Louie, Maggie C. ; Borowsky, Alexander D. ; Gao, Allen C. ; Evans, Christopher P. ; Lam, Kit S. ; Xu, Jianzhen ; Kung, Hsing Jien ; Evans, Ronald M. ; Xu, Yong ; Chen, Hong Wu. / ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. 於: Nature Medicine. 2016 ; 卷 22, 編號 5. 頁 488-496.
@article{19d9833f4f124b9288d6d9fb8d8504fa,
title = "ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer",
abstract = "The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.",
author = "Junjian Wang and Zou, {June X.} and Xiaoqian Xue and Demin Cai and Yan Zhang and Zhijian Duan and Qiuping Xiang and Yang, {Joy C.} and Louie, {Maggie C.} and Borowsky, {Alexander D.} and Gao, {Allen C.} and Evans, {Christopher P.} and Lam, {Kit S.} and Jianzhen Xu and Kung, {Hsing Jien} and Evans, {Ronald M.} and Yong Xu and Chen, {Hong Wu}",
year = "2016",
month = "5",
day = "1",
doi = "10.1038/nm.4070",
language = "English",
volume = "22",
pages = "488--496",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

AU - Wang, Junjian

AU - Zou, June X.

AU - Xue, Xiaoqian

AU - Cai, Demin

AU - Zhang, Yan

AU - Duan, Zhijian

AU - Xiang, Qiuping

AU - Yang, Joy C.

AU - Louie, Maggie C.

AU - Borowsky, Alexander D.

AU - Gao, Allen C.

AU - Evans, Christopher P.

AU - Lam, Kit S.

AU - Xu, Jianzhen

AU - Kung, Hsing Jien

AU - Evans, Ronald M.

AU - Xu, Yong

AU - Chen, Hong Wu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

AB - The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor-related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR-ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

UR - http://www.scopus.com/inward/record.url?scp=84961878425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961878425&partnerID=8YFLogxK

U2 - 10.1038/nm.4070

DO - 10.1038/nm.4070

M3 - Article

C2 - 27019329

AN - SCOPUS:84961878425

VL - 22

SP - 488

EP - 496

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -